HIV ACE

Targeting assembly of infectious HIV particles

Coordinatore	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)    more  Organization address address: 101 Rue de Tolbiac city: PARIS postcode: 75654 contact info Titolo: Ms. Nome: Lyddie Cognome: Laaland Email: send email Telefono: +33 1 40 78 49 35 Fax: +33 1 40 78 49 98
Nazionalità Coordinatore	France [FR]
Sito del progetto	http://www.hiv-ace.eu
Totale costo	4˙903˙156 €
EC contributo	3˙000˙000 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2007-A
Funding Scheme	CP-FP
Anno di inizio	2008
Periodo (anno-mese-giorno)	2008-03-01   -   2011-08-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)  Organization address address: 101 Rue de Tolbiac city: PARIS postcode: 75654 contact info Titolo: Ms. Nome: Lyddie Cognome: Laaland Email: send email Telefono: +33 1 40 78 49 35 Fax: +33 1 40 78 49 98	FR (PARIS)	coordinator	0.00
2	"USTAV ORGANICKE CHEMIE A BIOCHEMIE, AV CR, V.V.I."  Organization address address: FLEMINGOVO NAM. 542/2 city: PRAHA 6 postcode: 16610 contact info Titolo: Dr. Nome: Bozena Cognome: Petschova Email: send email Telefono: +420 220 183 275 Fax: +420 220 183 578	CZ (PRAHA 6)	participant	0.00
3	INSERM - TRANSFERT SA  Organization address address: Rue Watt 7 city: PARIS postcode: 75013 contact info Titolo: Mr. Nome: Louis Cognome: Jammayrac Email: send email Telefono: +33 155 03 01 01 Fax: +33 155030160	FR (PARIS)	participant	0.00
4	INSTITUT PASTEUR  Organization address address: RUE DU DOCTEUR ROUX 25-28 city: PARIS CEDEX 15 postcode: 75724 contact info Titolo: Dr. Nome: Nadia Cognome: Khelef Email: send email Telefono: +33 140 61 33 78 Fax: +33 140 61 39 40	FR (PARIS CEDEX 15)	participant	0.00
5	LABORATOIRE BIODIM  Organization address address: RUE DE GRENELLE 84 city: PARIS postcode: 75007 contact info Titolo: Ms. Nome: Séverine Cognome: Burdel Email: send email Telefono: 33157140525 Fax: 33157140524	FR (PARIS)	participant	0.00
6	MEDICAL RESEARCH COUNCIL  Organization address address: NORTH STAR AVENUE POLARIS HOUSE city: SWINDON postcode: SN2 1FL contact info Titolo: Ms. Nome: Claire Cognome: Hebblethwaite Email: send email Telefono: +44 20 7679 7259 Fax: +44 20 7679 7805	UK (SWINDON)	participant	0.00
7	UNIVERSITAETSKLINIKUM HEIDELBERG  Organization address address: IM NEUENHEIMER FELD 672 city: HEIDELBERG postcode: 69120 contact info Titolo: Mr. Nome: Thorsten Cognome: Brietz Email: send email Telefono: +49 6221 567086 Fax: +49 6221 565460	DE (HEIDELBERG)	participant	0.00
8	UNIVERSITE DE GENEVE  Organization address address: Rue du General Dufour 24 city: GENEVE postcode: 1211 contact info Titolo: Ms. Nome: Nicole Cognome: Mouthon Email: send email Telefono: +41 22 3795658 Fax: +41 22 3795702	CH (GENEVE)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'AIDS remains one of the major life threatening infectious diseases in the world today. A constant supply of novel antiretrovirals (ARVs) is needed to respond to the limitations of current drugs. By the end of 2007, the therapeutic arsenal against HIV is expected to comprise ARVs blocking all major steps of HIV replication, except for particle assembly and budding. Members of HIV-ACE were instrumental in recent breakthroughs concerning virus assembly and Envelope incorporation into virions. On the basis of novel and fully validated targets, the objectives of HIV-ACE are: i) Assay development, drug screening and pre-clinical development of small molecule inhibitors of Capsid assembly and Env incorporation, up to the stage of Early Drug Candidates with acceptable toxicity profile determined by ADME/Tox studies, activity against multi drug-resistant viral strains and primary non-B isolates, antiviral activity in primary T cells and macrophages (WP1); ii) Elucidation of 3D structures of these validated targets and rational drug design guided by molecular modelling and docking of inhibitors (WP2); iii) validation and exploitation of the HIV-susceptible transgenic rat model to allow preclinical in vivo-evaluation of novel drug candidates from HIV-ACE and to provide the European pharmaceutical industry with an efficient in vivo-platform for predictive testing of any kind of anti-HIV drug (WP3); iv) Elucidation of the mechanisms responsible for activity of the validated inhibitors, and discovery/validation of novel targets in the budding pathway of HIV-1 (WP4). HIV-ACE is composed of 8 teams from 5 European countries, including a Biopharma SME, led by prominent world-class scientists in Virology, Cell Biology, Immunology, Organic and Medicinal Chemistry, working in highly regarded research organisations. To efficiently achieve the ambitious goals of HIV-ACE, strong management led by a very experienced organisation has been included in a separate coordination-management WP5.'

Introduzione (Teaser)

Prevention and anti-viral therapy are the only current options to combating HIV spread. The discovery of anti-HIV drugs that act during the assembly, budding and release of HIV particles could improve the existing classical therapy directed against viral enzymes.